29 Dec 2022 07:00
Yourgene Health plc
("Yourgene" or the "Company")
Director/PDMR Shareholding
Manchester, UK - 29 December 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified on 28 December 2022 that Hayden Jeffreys, Chief Operating Officer of the Company, purchased 3,138,538 ordinary shares of 0.1p each in the Company ("Ordinary Shares") on 28 December 2022 at a price of 0.366p per share. Following the purchase, Hayden Jeffreys is interested in 3,827,482 Ordinary Shares, representing approximately 0.5 per cent. of the Company's issued share capital.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.The Directors of the Company take responsibility for this announcement.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com |
Barry Hextall, Chief Financial Officer |
|
Joanne Cross, Director of Marketing |
|
|
|
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 |
Liam Murray / Ludovico Lazzaretti | |
Singer Capital Markets (Corporate Broker) | Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Tom Salvesen / George Tzimas |
|
|
|
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com |
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / Mob: 07584 391 303 |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises integrated genomic technologies and services enabling genomic medicine in over 60 territories. The group works in partnership with global leaders in DNA technology to advance diagnostic science and support precision medicine.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and an extension into the precision medicine space with DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation platforms, and launched Yourgene Genomic Services in 2020, which has enabled Yourgene to offer a global laboratory service network equipped to provide high quality genetic testing and bioinformatics solutions and serve as a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Hayden Jeffreys
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Operating Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Yourgene Health plc | |||
b)
| LEI
| 213800UUIT8BZE7QEH33 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 0.1p each | |||
Identification code | ISIN: GB00BN31ZD89 | ||||
| |||||
b)
| Nature of the transaction
| Purchase of ordinary shares
| |||
c)
| Price(s) and volume(s) |
|
|
|
|
| Price(s) | Volume(s) |
| ||
0.366p | 3,138,538 | ||||
|
|
|
| ||
d)
| Aggregated information | N/A | |||
- Aggregated volume | |||||
- Price | |||||
e)
| Date of the transaction
| 28 December 2022 | |||
f)
| Place of the transaction
| UK | |||